National Institute of Mental Health; Notice of Closed Meetings, 22340 [2017-09701]
Download as PDF
<![CDATA[
22340
Federal Register / Vol. 82, No. 92 / Monday, May 15, 2017 / Notices
subgroup of products referred to as
‘‘covered tobacco products.’’
FDA is providing a 3-month extension
that applies to effective dates and
compliance deadlines for requirements
under the final rule set for May 10,
2017, or later and to all categories of the
newly regulated products, as well as the
addictiveness warning requirement for
RYO and cigarette tobacco.
The guidance represents the current
thinking of the FDA on this topic. It
does not establish any rights for any
person and is not binding on FDA or the
public. You can use an alternative
approach if it satisfies the requirements
of the applicable statutes and
regulations.
II. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information.
These collections of information are
subject to review by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995
(44 U.S.C. 3501–3520). The collections
of information in section 910(c)(1)(A)(i)
of the FD&C Act and 21 CFR part 1143
have been approved under OMB control
number 0910–0768; the collections of
information in section 905(j) of the
FD&C Act have been approved under
OMB control number 0910–0673; the
collections of information in section
904(a)(4) of the FD&C Act have been
approved under OMB control number
0910–0654; the collections of
information in 21 CFR part 1107 have
been approved under OMB control
number 0910–0684; the collections of
information in section 904(c)(1),
905(b),(c),(d), (h),and 905(i)(1) of the
FD&C Act have been approved under
OMB control number 0910–0650.
III. Electronic Access
jstallworth on DSK7TPTVN1PROD with NOTICES
Persons with access to the Internet
may obtain an electronic version of the
guidance at either https://
www.regulations.gov or https://
www.fda.gov/TobaccoProducts/
Labeling/RulesRegulationsGuidance/
default.htm.
Dated: May 10, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–09754 Filed 5–12–17; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
13:51 May 12, 2017
Jkt 241001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
Development of Psychosocial Therapeutic
and Preventive Interventions for Mental
Disorders.
Date: June 2, 2017.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel, Early
Stage Testing of Pharmacologic or Devicebased Interventions for the Treatment of
Mental Disorders.
Date: June 7, 2017.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: David I. Sommers, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, National Institutes of Health,
6001 Executive Blvd., Room 6154, MSC 9606,
Bethesda, MD 20892, 301–443–7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of
Mental Health Special Emphasis Panel,
BRAIN Initiative: Research on the Ethical
Implications of Advancements in
Neurotechnology and Brain Science (R01)
RFA.
Date: June 8, 2017.
Time: 12:00 p.m. to 4:00 p.m.
PO 00000
Frm 00036
Fmt 4703
Sfmt 4703
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852, (Telephone
Conference Call).
Contact Person: Megan Kinnane, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6148, MSC 9609,
Rockville, MD 20852–9609, 301–402–6807,
libbeym@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.242, Mental Health Research
Grants; 93.281)
Dated: May 9, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–09701 Filed 5–12–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Small
Business: HIV/AIDS Innovative Research
Applications.
Date: May 25, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Jingsheng Tuo, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
Bethesda, MD 20892, 301–451–8754, tuoj@
nei.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
E:\FR\FM\15MYN1.SGM
15MYN1
]]>Agencies
[Federal Register Volume 82, Number 92 (Monday, May 15, 2017)]
[Notices]
[Page 22340]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-09701]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel, Development of Psychosocial Therapeutic and
Preventive Interventions for Mental Disorders.
Date: June 2, 2017.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: David I. Sommers, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, National Institutes of Health, 6001 Executive Blvd.,
Room 6154, MSC 9606, Bethesda, MD 20892, 301-443-7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel, Early Stage Testing of Pharmacologic or Device-based
Interventions for the Treatment of Mental Disorders.
Date: June 7, 2017.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: David I. Sommers, Ph.D., Scientific Review
Officer, Division of Extramural Activities, National Institute of
Mental Health, National Institutes of Health, 6001 Executive Blvd.,
Room 6154, MSC 9606, Bethesda, MD 20892, 301-443-7861,
dsommers@mail.nih.gov.
Name of Committee: National Institute of Mental Health Special
Emphasis Panel, BRAIN Initiative: Research on the Ethical
Implications of Advancements in Neurotechnology and Brain Science
(R01) RFA.
Date: June 8, 2017.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852, (Telephone Conference
Call).
Contact Person: Megan Kinnane, Ph.D., Scientific Review Officer,
Division of Extramural Activities, National Institute of Mental
Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6148,
MSC 9609, Rockville, MD 20852-9609, 301-402-6807,
libbeym@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.242,
Mental Health Research Grants; 93.281)
Dated: May 9, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-09701 Filed 5-12-17; 8:45 am]
BILLING CODE 4140-01-P
